Navigation Links
TB vaccine candidate shows early promise
Date:9/4/2011

September 4, 2011 ─ (BRONX, NY) ─ Researchers at Albert Einstein College of Medicine of Yeshiva University report in the September 4 online edition of Nature Medicine that they have developed a tuberculosis (TB) vaccine candidate that proved both potent and safe in animal studies. (http://www.who.int/mediacentre/factsheets/fs104/en/) According to the World Health Organization, TB kills an estimated 1.7 million people each year and infects one out of three people around the globe. With drug-resistant strains spreading, a vaccine for preventing TB is urgently needed.

"Producing effective TB vaccines requires a better understanding of the mechanisms used by Mycobacterium tuberculosis [the bacterial species that causes TB] to evade the body's immune responses," said senior author William Jacobs, Jr., Ph.D., professor of microbiology & immunology and of genetics at Einstein and a Howard Hughes Medical Institute investigator. He notes that the only currently used vaccine, the Bacille Calmette-Gurin (BCG) vaccine, has been notoriously inconsistent in protecting against TB.

To determine how M. tuberculosis outwits the immune response, Dr. Jacobs and his colleagues worked with a closely related species known as Mycobacterium smegmatis that is lethal to mice at high doses but does not harm people. The researchers created a version of M. smegmatis lacking a set of genes, known as ESX-3, considered crucial for evading host immunity. When high doses of the altered bacteria were infused into mice, it became clear that bacteria lacking the ESX-3genes could no longer evade their hosts' immune system: the mice controlled and cleared th
'/>"/>

Contact: Kim Newman
Sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Scripps Research scientists create vaccine against heroin high
2. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
3. Discovery of natural antibody brings a universal flu vaccine a step closer
4. Innovative vaccines with nanotechnology
5. Adjuvant combo shows potential for universal influenza vaccine
6. Study shows the HPV vaccine Gardasil doesnt increase disease activity in SLE patients
7. 2020 vision of vaccines for malaria, TB and HIV/AIDS
8. Vaccine protects from deadly Hendra virus
9. Celiac disease vaccine shows promising results in Phase I trial
10. Study identifies promising target for AIDS vaccine
11. HIV protein unveils vaccine target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... OXFORD, CT ., Aug. 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... wallet, announces it has joined The Smart Card Alliance ... the Smart Card Alliance and the Smart Card Alliance ... and visibility to industry peers and thought leaders promoting ...
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... the McKnight Brain Institute of the University of Florida ... other diseases by plundering the secrets of regeneration from ... newts, starfish and flatworms. , Fueled by about $6 ... funds, "The Regeneration Project" will connect scientists who work ...
... how different species use common genes to control their ... to accommodate their own features. The findings, which were ... Small’s laboratories in NYU’s Center for Developmental Genetics, offer ... species. The study is published in the latest issue ...
... medical practice that an antiretroviral drug widely used to treat ... own in patients co-infected with HIV. Their findings demonstrate ... drugs used to treat the AIDS virus. , "Our results ... has been shown to be active against HIV - it ...
Cached Biology News:Research project tackles 'regeneration' gap 2Research project tackles 'regeneration' gap 3NYU scientists identify how development of different species uses same genes with distinct features 2Widely used hepatitis B drug spurs HIV drug resistance 2Widely used hepatitis B drug spurs HIV drug resistance 3
(Date:9/3/2015)... ... September 03, 2015 , ... Michigan-based technology ... wearable early 2016. , The device, called the Halo H1, is a ... electrical sensing technology. These sensors track trending interstitial fluid levels in the body, ...
(Date:9/2/2015)... 2015 Axovant Sciences Ltd. (NYSE:  AXON), a leading ... announced upcoming presentations at three investor conferences: , ... Healthcare Conference in New York at ... at 2:00 PM at the BioCentury NewsMakers Conference in ... & Conference Center , Thursday, September 17 at 9:30 ...
(Date:9/2/2015)... Ill. (PRWEB) , ... September ... ... leading provider of regulatory compliance, quality systems, analytical testing, education and consulting ... firm with expertise in medical device products/processes development, design control, validation, quality ...
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "Biochips and ... their offering. This report is an ... applications. The report starts with a description of ... Technologies include array comparative genomic hybridization (CGH), copy ...
Breaking Biology Technology:Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2
... Newly formed Advisory Board to advise on cancer screening ... mitochondrial DNA-based ... Inc. (OTC,Bulletin Board: TBIO) today announced that it has ... the latest developments and,scientific opportunities in cancer detection screening ...
... ... Use, LA JOLLA, Calif., Jan. 17 Stemagen, a privately ... in the world to create, and meticulously document, a cloned human,embryo ... Wood, M.D., Ph.D., a co-author of the,publication and a donor of ...
... Trial will also Support a Marketing Authorization Application in the ... ... Agennix Incorporated announced today,that the U.S. Food and Drug Administration ... evaluating its lead molecule,talactoferrin alfa, in combination with chemotherapy as first-line,treatment ...
Cached Biology Technology:Transgenomic, Inc. Forms Scientific Advisory Board 2Transgenomic, Inc. Forms Scientific Advisory Board 3Stemagen First to Create Cloned Human Embryos From Adult Cells 2Stemagen First to Create Cloned Human Embryos From Adult Cells 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5
...
...
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
Biology Products: